Treatment of Peri-implantitis Lesions by Using Biomaterial

Peri-implantitis Clinical Trial

Official title: Surgical Treatment of Peri-implantitis Lesions, With or Without the Placement of a Bone Substitute and a Collagen Membrane. A Randomized Clinical Trial

Status Completed

Clinical Trial Summary

The primary objective of the study is to proof the successful use of Geistlich Bio-Oss® and Geistlich Bio-Gide® (already registered medical devices) in bony peri-implant defects due to peri-implantitis disease.

Clinical Trial Description

Patient who will considered eligible at the screening visit will undergo surgical treatment procedure within 2 weeks. At the day of the surgery the patients will be randomized into the 2 treatment groups.

The subjects will be then prescribed postoperative antibiotics (Azitromax 500 mg day one and 250 mg day 2-4).

Post-operative pain will be controlled with Ibuprofen (400mg x 3) for two days to all subjects. Subjects will rinse twice daily with Chlorhexidine mouth rinse and use modified oral hygiene procedures during the first 5 weeks of healing. Subjects will receive professional prophylaxis as required.

Subjects will be instructed on appropriate oral hygiene throughout the study and will be given appropriate oral hygiene instructions. Instructions on post-operative care will be repeated at each visit. In particular the following points have to be covered during the first month after surgery: Chlorhexidine rinses, avoidance of brushing, usage of interdental cleaning devices, avoidance of chewing on or trauma to the treated area. In addition subjects will be instructed not to smoke more than 10 cigarettes per day during the entire study period and not to consume alcohol during antibiotic therapy.

Sutures will be removed after 14 days. Photos will be taken during the whole study to document the healing process.

Further follow up visits will be scheduled 6 weeks and 3,6,9,12 months post-surgery. ;

Related Conditions & MeSH terms

• Peri-implantitis

• NCT number: NCT02375750
• Study type: Interventional
• Source: Geistlich Pharma AG
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Completion date: April 2017